Compelling research points to the substantial benefits of increasing access to screening for osteoporosis.
Read More
The National Osteoporosis Foundation (NOF) is pleased to submit its comments to the above referenced Proposed Rule promulgated by the Department of Health and Human Services (HHS) to remove Anti-Kickback Statute (AKS) safe harbor protection for manufacturer prescription drug rebates in connection with…
Read More
The National Osteoporosis Foundation (NOF) is pleased to submit its comments to the above- referenced proposed rule entitled “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out of Pocket Expenses (the Proposed Rule). We previously responded…
Read More
NOF understands that the IPI Model would leverage both the waiver authority of the Center for Medicare and Medicaid Innovation (CMMI) and the statutory provisions authorizing a…
Read More